Related Experiment Video
Updated: Feb 25, 2026
09:41
Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro
Published on: March 17, 2023
3.8K
Adiponectin and its Hydrolase-Activated Receptors
Ankit X Sharma1, William L Holland1
1Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX 75390-8549, USA.
Journal of Nature and Science
|August 1, 2017
Summary
Adiponectin combats obesity-induced insulin resistance by reducing harmful ceramides and increasing beneficial sphingosine-1-phosphate (S1P). Targeting adiponectin receptors offers a promising therapy for type II diabetes.
Area of Science:
- Metabolic pathways
- Endocrinology
- Lipid metabolism
Background:
- Adiponectin is crucial for insulin sensitivity, acting via AdipoR1 and AdipoR2 receptors.
- Ceramide accumulation contributes to insulin resistance in obesity.
- Sphingosine-1-phosphate (S1P) production by adiponectin enhances metabolic benefits.
Purpose of the Study:
- To review current knowledge on the adiponectin signaling pathway.
- To provide new insights into adiponectin receptor characteristics.
- To affirm adiponectin receptor agonism as a therapeutic strategy.
Main Methods:
- Literature review of recent research on adiponectin signaling.
- Analysis of adiponectin receptor functions.
- Evaluation of therapeutic potential for metabolic disorders.
Main Results:
- Adiponectin signaling pathways are better understood.
- Adiponectin receptors exhibit notable characteristics.
- Adiponectin receptor agonism shows therapeutic promise.
Conclusions:
- Adiponectin receptor agonism is a viable strategy to reduce ceramide levels.
- This approach can improve insulin sensitivity in obese patients with type II diabetes.
- Targeting adiponectin signaling offers a new therapeutic avenue for metabolic diseases.
More Related Videos
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
4.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
4.5K
01:28Insulin: The Receptor and Signaling Pathways
4.7K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
4.7K
01:09GPCRs Regulate Adenylyl Cylase Activity
7.8K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.8K
01:22PI3K/mTOR/AKT Signaling Pathway
5.8K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.8K
01:31Adrenergic Receptors: ɑ Subtype
3.1K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.1K
01:38Receptor-mediated Endocytosis
112.2K
Overview
112.2K